Vanguard Capital Management
KPTI icon

Vanguard Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Vanguard Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.37M Buy
958,979
+219,234
+30% +$1.9M ﹤0.01% 2853
2026
Q1 		$4.12M Buy
+739,745
New +$5.64M ﹤0.01% 3133

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $140M AUM

Vanguard Capital Management's KPTI Position: Q2 2026 in Review

Vanguard Capital Management increased its Karyopharm Therapeutics (KPTI) stake by 30% in Q2 2026, buying an estimated $1.9M and bringing the position to 958,979 shares worth $9.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2853.

Vanguard Capital Management first reported a position in KPTI in Q1 2026 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Vanguard Capital Management held 958,979 shares of Karyopharm Therapeutics worth $9.37M as of Q2 2026.
  • Vanguard Capital Management bought 219,234 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Karyopharm Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2853 holding.
  • Vanguard Capital Management first reported a position in Karyopharm Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.